CHANGING THE FUTURE
Dwight H. Egan; Chief Executive Officer
Mr. Egan has been an officer and director since April 2013. Mr. Egan has been engaged in private investment business from February 1999 to the present. He was a senior executive at Data Broadcasting Corporation, a leading provider of wireless, real-time financial market data, news and sophisticated fixed- income portfolio analytics to 27,000 individual and professional investors from 1995 to 1999. He co-founded and served as CEO and Chairman of the Board of Broadcast International, Inc. from 1984 to 1995, when Data Broadcasting Corporation acquired Broadcast International and created CBS MarketWatch, a leading financial news site and participated in its initial public offering. Mr. Egan’s prior experience in directing a public company and working with capital markets gives him valuable experience in advising the board on matters of finance and operations.
Brian L. Brown, CPA; Chief Financial Officer
Mr. Brown was appointed Chief Financial Officer in February 2021. Previously, he served as Chief Financial Officer of A-Core Concrete Cutting, Inc., a privately held specialty construction company, and was Vice President of Accounting, Treasury & Investor Relations, in addition to Director of Finance, for Sportsman’s Warehouse Holdings, Inc. (Nasdaq: SPWH), a publicly traded outdoor sporting goods retailer. Prior to becoming a Certified Public Accountant in 2007, Mr. Brown received his Master of Professional Accountancy (MPrA) degree from the University of Utah David Eccles School of Business in 2001 and a Bachelor of Arts Degree in Accounting from the University of Utah in 2000. Mr. Brown’s experience in finance, accounting, and roles directing successful financial departments all help make Mr. Brown a critical component of the Co-Diagnostics management team.
Jesse Montgomery, PhD; Chief Scientific Officer
Dr. Montgomery was appointed Chief Scientific Officer in February 2021. Previously, he served as Senior Vice President of Biochemistry and Director of Research and Development. His contributions to the company include leading the development of several panels such as the influenza A/B and SARS-CoV-2 multiplex “ABC” test, the two-gene SARS-CoV-2 test, and the SARS-CoV-2 Direct Saliva test. He also developed the Company’s patent-pending single-step NGS library preparation technology. Dr. Montgomery received his PhD from the University of Utah in Bioengineering studying under Carl Wittwer, a pioneer in PCR technology. From there he worked as a scientist in the Research and Innovation Department at BioFire Diagnostics, and later as a scientist in bioinformatics at IDbyDNA where he developed algorithms for metagenomics sequencing. Dr. Montgomery is a driven innovator committed to Co-Diagnostics’ vision of delivering accessible diagnostics solutions to address global health challenges. He is excited to be part of such a talented team and to lead Co-Diagnostics into new frontiers.
Mayuranki Almaula, PhD; Sr. VP Overseas Operations and Strategic Alliances
Dr. Almaula is responsible for establishing clinical verification and validation strategies that support our diagnostic portfolios. This involves supporting the India-based clinical and manufacturing operations for our joint venture, CoSara Diagnostics Pvt Ltd. Dr. Almaula has provided support in establishing relationships across multiple continents for companies including Insilico Sciences, as Business Development Director, Gen Probe (now Hologic), as supporting the Senior Executive VP of Business Development in defining and executing their India strategy, and Symbiosis Biowares in their International Business Development strategy. Mayuranki completed a Masters in Microbiology from Maharaja Sayajirao University Baroda, and a doctorate in Microbiology from Stanford University.
Cameron Gundry; Head of Commercialization LATAM/EUR
Mr. Gundry has over 20 years’ experience in qPCR technique invention, instrument and clinical assay manufacture, product development and management, and commercialization of molecular diagnostic products. Mr. Gundry’s background also includes 18 years with BioFire Diagnostics, working closely with that company’s founders, a Master’s of Science in Lab Medicine and Biomedical Science from the University of Utah, and peer-reviewed papers, book chapters, and PCR-related patents that have collectively been cited more than 2,000 times. Currently, Cameron brings his breadth of experience to bear in overseeing the sales and commercialization efforts of the Company’s products throughout Latin America and Europe.
Research and Development
Rebecca A. Garcia, PhD, MLT (ASCP)CM; VP of Product Development
Dr. Garcia’s direction has been instrumental in Co-Diagnostics acquiring ISO-13485 certification, the Company’s development of over 20 assays, several of which are approaching product launch in 2019, and global expansion of testing and manufacturing. She has extensive experience developing and translating molecular diagnostic assays for clinical application. Dr. Garcia is co-inventor of several Co-Diagnostic’s patented technologies. She finished her doctoral degree in Healthcare Genetics from Clemson University and B.A. in Natural Sciences with an emphasis in Biology from Erskine College. Dr. Garcia has several publications and continues to present at conferences and workshops. She is an avid supporter of genomic health policy and global healthcare initiatives.
Jana Kent, PhD; Senior Research Scientist
Dr. Kent develops novel applications of the Company’s proprietary and patented technology, often facilitated through partnerships with agricultural and other biotechnology firms. More recently this has included high-throughput testing for SNP detection with CoPrimers for agriculture and liquid biopsy uses. Dr. Kent received her doctorate in Molecular Biology and Genetics from the Institute of Inherited Metabolic Disorders, Charles University (Prague). Her past experience includes time with the University of Colorado Health Sciences Center, and the Wittwer Laboratory for DNA Analysis at the University of Utah.